# Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

> **NCT00636805** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 63 (actual)

## Conditions studied

- Brain Cancer

## Interventions

- **DRUG:** Palonosetron (Aloxi) and Dexamethasone

## Key facts

- **NCT ID:** NCT00636805
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Study was halted early after 63 subjects were enrolled due to slow accrual.
- **Last updated:** 2014-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636805, "Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00636805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*